BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21079519)

  • 1. The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies.
    Porcel JM; Esquerda A; Rodriguez-Panadero F; Martínez-Iribarren A; Bielsa S
    J Thorac Oncol; 2011 Jan; 6(1):190-4. PubMed ID: 21079519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A; Lynne LC; Howell L
    Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
    Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
    J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.
    Fuhrman C; Duche JC; Chouaid C; Abd Alsamad I; Atassi K; Monnet I; Tillement JP; Housset B
    Clin Biochem; 2000 Jul; 33(5):405-10. PubMed ID: 11018693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
    Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
    Kirschner MB; Pulford E; Hoda MA; Rozsas A; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; László V; Klikovits T; Vallely MP; Grusch M; Hegedus B; Dome B; Klepetko W; van Zandwijk N; Klebe S; Reid G
    Br J Cancer; 2015 Sep; 113(6):963-9. PubMed ID: 26263483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
    Dejmek A
    Acta Cytol; 2008; 52(5):579-83. PubMed ID: 18833821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
    Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
    Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
    Leers MP; Aarts MM; Theunissen PH
    Histopathology; 1998 Mar; 32(3):209-16. PubMed ID: 9568505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
    Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
    Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
    Klech H; Rona G; Hutter C; Bayer PM; Kummer F
    Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma.
    Fujimoto N; Gemba K; Asano M; Fuchimoto Y; Wada S; Ono K; Ozaki S; Kishimoto T
    Respir Investig; 2013 Jun; 51(2):92-7. PubMed ID: 23790737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR; Zhai J
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
    Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
    Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High CD44 expression on human mesotheliomas mediates association with hyaluronan.
    Penno MB; Askin FB; Ma H; Carbone M; Vargas MP; Pass HI
    Cancer J Sci Am; 1995; 1(3):196-203. PubMed ID: 9166476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].
    Inoue C; Kato S; Higuchi K; Inoue H
    Nihon Kokyuki Gakkai Zasshi; 2007 Mar; 45(3):243-7. PubMed ID: 17419436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
    Alemán C; Manuel Porcel J; Ma Segura R; Alegre J; Esquerda A; Ruiz E; Bielsa S; de Sevilla TF
    Med Clin (Barc); 2009 Oct; 133(12):449-53. PubMed ID: 19783262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.